SEARCH:   Advanced

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Inwards, D. J. Search for Related Content PubMed Articles by Inwards, D. J. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 July 2003, Vol. 102, No. 1, pp. 2 Positron emission tomography predicts transplantation outcome High-dose chemotherapy with hematopoietic stem cell transplantation has become a mainstay of treatment for patients with non-Hodgkin lymphoma or Hodgkin lymphoma who either fail to achieve a complete remission or who have relapsed disease. As investigators analyzed the results of this approach, it quickly became apparent that disease status and chemotherapy sensitivity were powerful prognostic factors (Philip et al, N Engl J Med. 1987;316:1493-1498). More recently, it has been shown that early lymphocyte recovery after stem cell transplantation is strongly associated with improved progression-free survival, though this prognostic factor cannot be assessed prior to transplantation (Porrata et al, Blood. 2001;98:579-585). Positron emission tomography performed either partway through conventional chemotherapy or at the close of therapy has been shown to be predictive of outcome in Hodgkin lymphoma and non-Hodgkin lymphoma (Spaepen et al, J Clin Oncol. 2001;19:414-419). In this issue, Spaepen and colleagues (page 53) report the results of a retrospective analysis of the predictive value of positron emission tomography performed after salvage therapy prior to stem cell transplantation in patients with non-Hodgkin lymphoma or Hodgkin lymphoma. Of 30 patients with a negative study prior to transplantation, 25 remained in remission while 2 succumbed to treatment-related mortality and 3 had relapsed disease. Of 30 patients with abnormal 18F-fluorodeoxyglucose (FDG) uptake prior to transplantation, 26 had progressive lymphoma after transplantation. The 4 patients with false-positive results (abnormal uptake but no disease progression) appeared to have had uptake related to either infection (2 cases) or irradiation prior to the study (2 cases). If these findings are confirmed by larger prospective trials, routine positron emission tomography prior to hematopoietic stem cell transplantation may become the new standard for assessing chemotherapy sensitivity. It will be important for false-positive results to be identified so that patients are not erroneously excluded from transplantation based on an overestimated risk of relapse. David James Inwards Mayo Clinic CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation Karoline Spaepen, Sigrid Stroobants, Patrick Dupont, Peter Vandenberghe, Johan Maertens, Guy Bormans, José Thomas, Jan Balzarini, Christine De Wolf-Peeters, Luc Mortelmans, and Gregor Verhoef Blood 2003 102: 53-59. [Abstract] [Full Text] [PDF] This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Inwards, D. J. Search for Related Content PubMed Articles by Inwards, D. J. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020